These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
514 related articles for article (PubMed ID: 22722778)
1. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Bomback AS; Canetta PA; Beck LH; Ayalon R; Radhakrishnan J; Appel GB Am J Nephrol; 2012; 36(1):58-67. PubMed ID: 22722778 [TBL] [Abstract][Full Text] [Related]
2. Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series. Madan A; Mijovic-Das S; Stankovic A; Teehan G; Milward AS; Khastgir A BMC Nephrol; 2016 Mar; 17():37. PubMed ID: 27036111 [TBL] [Abstract][Full Text] [Related]
3. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. Li X; Li H; Ye H; Li Q; He X; Zhang X; Chen Y; Han F; He Q; Wang H; Chen J Am J Kidney Dis; 2009 Jul; 54(1):51-8. PubMed ID: 19406543 [TBL] [Abstract][Full Text] [Related]
4. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Bomback AS; Tumlin JA; Baranski J; Bourdeau JE; Besarab A; Appel AS; Radhakrishnan J; Appel GB Drug Des Devel Ther; 2011 Mar; 5():147-53. PubMed ID: 21448451 [TBL] [Abstract][Full Text] [Related]
5. Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Hogan J; Bomback AS; Mehta K; Canetta PA; Rao MK; Appel GB; Radhakrishnan J; Lafayette RA Clin J Am Soc Nephrol; 2013 Dec; 8(12):2072-81. PubMed ID: 24009220 [TBL] [Abstract][Full Text] [Related]
6. Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS). Yamamoto R; Imai E; Maruyama S; Yokoyama H; Sugiyama H; Nitta K; Tsukamoto T; Uchida S; Takeda A; Sato T; Wada T; Hayashi H; Akai Y; Fukunaga M; Tsuruya K; Masutani K; Konta T; Shoji T; Hiramatsu T; Goto S; Tamai H; Nishio S; Shirasaki A; Nagai K; Yamagata K; Hasegawa H; Yasuda H; Ichida S; Naruse T; Nishino T; Sobajima H; Tanaka S; Akahori T; Ito T; Terada Y; Katafuchi R; Fujimoto S; Okada H; Ishimura E; Kazama JJ; Hiromura K; Mimura T; Suzuki S; Saka Y; Sofue T; Suzuki Y; Shibagaki Y; Kitagawa K; Morozumi K; Fujita Y; Mizutani M; Shigematsu T; Kashihara N; Sato H; Matsuo S; Narita I; Isaka Y Clin Exp Nephrol; 2020 Jun; 24(6):526-540. PubMed ID: 32146646 [TBL] [Abstract][Full Text] [Related]
8. Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum. Stokes MB; Markowitz GS; Lin J; Valeri AM; D'Agati VD Kidney Int; 2004 May; 65(5):1690-702. PubMed ID: 15086908 [TBL] [Abstract][Full Text] [Related]
9. A modern approach to selectivity of proteinuria and tubulointerstitial damage in nephrotic syndrome. Bazzi C; Petrini C; Rizza V; Arrigo G; D'Amico G Kidney Int; 2000 Oct; 58(4):1732-41. PubMed ID: 11012907 [TBL] [Abstract][Full Text] [Related]
10. Cyclosporine in idiopathic nephrotic syndrome. Ponticelli C Immunopharmacol Immunotoxicol; 1993 Aug; 15(4):479-89. PubMed ID: 8227973 [TBL] [Abstract][Full Text] [Related]
11. The efficacy of cyclosporine A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis: a multicenter study in Korea. Lee HY; Kim HS; Kang CM; Kim SG; Kim MJ Clin Nephrol; 1995 Jun; 43(6):375-81. PubMed ID: 7554521 [TBL] [Abstract][Full Text] [Related]
12. Outcomes of primary nephrotic syndrome in elderly Japanese: retrospective analysis of the Japan Renal Biopsy Registry (J-RBR). Yokoyama H; Sugiyama H; Narita I; Saito T; Yamagata K; Nishio S; Fujimoto S; Mori N; Yuzawa Y; Okuda S; Maruyama S; Sato H; Ueda Y; Makino H; Matsuo S Clin Exp Nephrol; 2015 Jun; 19(3):496-505. PubMed ID: 25230687 [TBL] [Abstract][Full Text] [Related]
13. Leveraging melanocortin pathways to treat glomerular diseases. Gong R Adv Chronic Kidney Dis; 2014 Mar; 21(2):134-51. PubMed ID: 24602463 [TBL] [Abstract][Full Text] [Related]
14. Long-term ciclosporine A treatment in adults with minimal change nephrotic syndrome or focal segmental glomerulosclerosis. Ittel TH; Clasen W; Fuhs M; Kindler J; Mihatsch MJ; Sieberth HG Clin Nephrol; 1995 Sep; 44(3):156-62. PubMed ID: 8556831 [TBL] [Abstract][Full Text] [Related]
15. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis. Dumoulin A; Hill GS; Montseny JJ; Meyrier A Am J Kidney Dis; 2003 Jan; 41(1):38-48. PubMed ID: 12500220 [TBL] [Abstract][Full Text] [Related]
16. [Effect of cyclosporin A on renal function in patients with glomerulonephritis]. Heering P; Schneider A; Grabensee B; Plum J Dtsch Med Wochenschr; 2001 Oct; 126(40):1093-8. PubMed ID: 11588659 [TBL] [Abstract][Full Text] [Related]
17. Use of Rituximab as an Off-Label Medication in Glomerular Diseases: Clinical Perspective. AlSahow A; Al-Muhaiteeb A; Nawar H; AlHelal B; AlYousef A; Abdallah E; AbuShall A; Elmekawi S; Meshal B; AlQallaf A; AlRajab H Med Princ Pract; 2022; 31(2):133-141. PubMed ID: 35021170 [TBL] [Abstract][Full Text] [Related]
18. Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome. Zietse R; Wenting GJ; Kramer P; Schalekamp MA; Weimar W Clin Sci (Lond); 1992 Jun; 82(6):641-50. PubMed ID: 1320544 [TBL] [Abstract][Full Text] [Related]
19. Partial remission of resistant nephrotic syndrome after oral galactose therapy. Kopač M; Meglič A; Rus RR Ther Apher Dial; 2011 Jun; 15(3):269-72. PubMed ID: 21624074 [TBL] [Abstract][Full Text] [Related]